Eye drops/treatment to heal stubborn cornea surface damage
Treatments studied
Part of Eyes & vision, Infections clinical trials.
This Phase 2 trial tests a locally delivered cell-based treatment (allogeneic mesenchymal stromal cells) to help heal long-lasting damage to the eye’s clear surface (the cornea). It may help if your cornea epithelium (surface layer) won’t improve even after standard non-surgical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your affected eye has reduced vision but not too good: at or worse than 20/32 (best corrected).
- Your cornea surface defect or problem has not improved after at least 2 weeks of standard non-surgical care.
- Your eye shows signs the cornea surface barrier is not working well (measured with fluorescein staining).
- Your corneal nerve/“neurotrophic” disease is in stage 1–3, and the damaged area is not more than about 80% of the cornea diameter.
- You must be able and willing to follow all study visits and instructions, and sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special substance from stem cells (called secretome) can help heal chronic surface problems on the eye that haven't gotten better with standard treatments. It's for people with a stubborn scratch or defect on the cornea that has lasted more than 14 days.
This trial tests if using special cells from your own urine can help repair the inner layer of your cornea (the clear front part of your eye). It may be an option if you have damage to these cells and have already had at least one cornea transplant.
This trial tests transplanting your own limbal and corneal stromal stem cells to repair corneal damage from a chemical burn. It may help if standard treatments have not improved your eye surface.
This Phase 2 trial tests BRM424 eye drops in adults with neurotrophic keratitis (a weakened, slow-healing cornea) to see if they help and are safe over 28 days. You may be able to join if your condition matches Stage 2 or Stage 3 and you meet the safety rules.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This study tests whether cenegermin eye drops help heal stubborn corneal ulcers (open sores on the clear front of the eye) that haven't improved with standard treatments like lubricating drops or contact lenses.
Hear when a new Corneal Ulcer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.